NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.
NCT00318266
·
clinicaltrials.gov ↗
COMPLETED
Status
73
Enrollment
OTHER
Sponsor class
Conditions
Bladder Cancer
Interventions
DEVICE:
Nuclear Matrix Protein 22 Urine sample kit
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's